Key Points
- CEO Joseph Sardano bought 30,000 shares for $72,000 at an average price of $2.40, increasing his stake by 2.46% to 1,250,293 shares.
- Sensus Healthcare missed quarterly expectations, reporting a loss of $0.09 per share versus the $0.06 expected and revenue of $6.0 million versus $6.61 million forecast.
- Analysts’ consensus rating is Moderate Buy, with an average price target of $5.83; ratings include four Buys and one Sell.
Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) CEO Joseph Sardano acquired 30,000 shares of the firm's stock in a transaction that occurred on Monday, November 16th. The stock was acquired at an average price of $2.40 per share, with a total value of $72,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,250,293 shares in the company, valued at $3,000,703.20. This trade represents a 2.46% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Sensus Healthcare Stock Performance
Shares of SRTS stock opened at $2.26 on Wednesday. The company's 50 day moving average price is $2.94 and its two-hundred day moving average price is $3.42. Sensus Healthcare, Inc. has a 52 week low of $2.14 and a 52 week high of $5.49.
Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.03). The company had revenue of $6.00 million during the quarter, compared to the consensus estimate of $6.61 million. Sensus Healthcare had a negative net margin of 96.49% and a negative return on equity of 24.95%.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on SRTS shares. Weiss Ratings cut shares of Sensus Healthcare from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday. Alliance Global Partners reaffirmed a "buy" rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Finally, Lake Street Capital lowered their target price on Sensus Healthcare from $4.50 to $4.00 and set a "buy" rating for the company in a report on Friday, August 14th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $5.83.
View Our Latest Stock Report on Sensus Healthcare
Hedge Funds Weigh In On Sensus Healthcare
A number of large investors have recently bought and sold shares of the company. Allworth Financial LP acquired a new position in Sensus Healthcare during the 3rd quarter worth approximately $209,000. Cetera Investment Advisers acquired a new stake in shares of Sensus Healthcare in the third quarter valued at approximately $48,000. EP Wealth Advisors LLC acquired a new stake in shares of Sensus Healthcare in the second quarter valued at approximately $49,000. BlackRock Inc. acquired a new stake in shares of Sensus Healthcare in the second quarter valued at approximately $252,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Sensus Healthcare in the second quarter valued at approximately $303,000. Institutional investors and hedge funds own 25.30% of the company's stock.
About Sensus Healthcare
(
Get Free Report)
Sensus Healthcare, Inc. develops and markets medical devices for the treatment of non-melanoma skin cancer and other skin conditions. Its products use superficial radiation therapy, which delivers low-energy X-rays to targeted areas of the skin. The company's product portfolio includes the SRT-100 platform and related systems designed for use in clinical settings. Sensus positions these technologies as non-invasive treatment options for conditions including basal and squamous cell skin cancers and keloids.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].